Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25.

ABSTRACT:

Background

In advanced urothelial carcinoma (UC), the prognostic impact of metastatic site and burden during avelumab maintenance therapy remains poorly defined.

Methods

We performed a sub-analysis of the Italian multicenter retrospective-prospective observational study Meet-URO 25, including patients with advanced UC who received avelumab maintenance after disease control with first-line platinum-based chemotherapy. We assessed the association between metastatic site and number of metastatic sites at the start of avelumab and clinical outcomes, including objective response rate (ORR), progression-free survival (PFS), and overall survival (OS).

Results

A total of 243 patients were included. Lymph nodes (79.0%), lungs (32.1%), and bones (27.2%) were the most common met

SUBMITTER: Roviello G 

PROVIDER: S-EPMC12906447 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature